Resources
BNET Resources
- sort by:
- Relevance
- Date
- Popularity
- Forest Laboratories Inc. F1Q10 (Qtr End 06/30/09) Earnings Call Transcript
- Question-and-Answer Session Operator Operator Instructions. And our first question comes from Tim Chiang with FTN Equity Capital. Tim Chiang - FTN Equity Capital I had a question about some of the guidance numbers that you provided last quarters and sort of given the strong uptake of Savella, why you're...
- Earnings calls 2009-07-21
Additional Resources
- Forest Laboratories Inc. and Cypress Bioscience Inc. won approval for their drug Savella for the management of fibromyalgia
- Forest Laboratories Inc. New York and Cypress Bioscience Inc. San Diego CA won approval for their drug Savella for the management of fibromyalgia. Fibromyalgia is a chronic condition characterized by widespread pain and decreased physical function, afflicting as many as six million people in the United States. The...
- Research articles 2009-01-19
- Forest Laboratories Inc., F3Q09 (Qtr End 12/31/08) Earnings Call Transcript
- Question-and-Answer Session Operator Operator Instructions. The first question comes from the line of Gregory Gilbert with Bank of America-Merrill Lynch. Gregory Gilbert - Bank of America-Merrill Lynch First for Frankie, discuss any changes in trade inventory levels for your key products and also for clarification on that $70...
- Earnings calls 2009-01-20
- Forest Labs Q1: $170 Million Fee for DOJ; Its Numbers Are Written in "Invisible Ink"
- Forest Labs is holding a $170 million contingency fee in case it needs to settle allegations by the Department of Justice that it bribed doctors --- with such things as $1,000 gift certificates to Alain Ducasse -- into prescribing Lexapro and Celexa for children even though it was not approved...
- Blog posts 2009-04-23
- Elsewhere, Cypress Bioscience Inc. jumped $2.10, or 29%, to $9.44
- Elsewhere, Cypress Bioscience Inc. Nasdaq jumped $2.10, or 29%, to $9.44. The company and partner Forest Laboratories Inc. NYSE won approval for their drug Savella for the management of fibromyalgia. Fibromyalgia is a chronic condition characterized by widespread pain and decreased physical function, afflicting as many as six...
- Research articles 2009-01-19
- Forest Labs: Concerned About Pipeline
- Zacks.com submits: By Jason Napodano, CFA & Brian Marckx, CFA Forest Laboratories, Inc.'s FRX financial results for 2009 were inline with our expectations. EPS fell 3% on revenue growth of 2% as operating cost growth outpaced that of revenue. SG&A expenses grew 10%, reflecting increased costs related to...
- External links 2009-06-18
- << Previous
- page 1 of 1
- Next >>
Presented by American Express